Clinical trial for personalized medicine in depression.
| Project/Area Number |
23591684
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
KATO Masaki 関西医科大学, 医学部, 准教授 (00351510)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 精神薬理学 / 無作為比較試験 / 遺伝薬理 / 個別化治療 / 薬理遺伝 / うつ病 / 治療反応予測 / 無作為臨床比較試験 / ミルタザピン / SSRI |
|---|
| Outline of Final Research Achievements |
RCT of SSRI and mirtazapine including 150 depressive patients for 12 weeks resulted that mirtazapine showed faster remission than SSRIs. In non-responder at week 4, no difference was seen between the monotherapy and the combination group. We confirmed that EPI confers a large contribution to the treatment response at week 6 to paroxetine and milnacipran and less to fluvoxamine and genetic variants in ADRA2A and HTRA1A also influenced milnacipran response and 5-HTTLPR and FGF2 influenced fluvoxamine response in the multiple linear regression analysis. A genome-wide association study was performed using data from 865 subjects of ISPC. Top association results in the meta-analysis of response included SNPs in the HPRTP4 /VSTM5 region, which approached genome-wide significance and SNPs in NRG1. A pathway analysis identified the SNPs on JUN, CREB1 and RELA genes within the regulatory region nucleic acid binding pathway as an possible predictors of SSRI response.
|
Report
(5 results)
Research Products
(18 results)
